Trials / Unknown
UnknownNCT01163058
Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer
Retrospective Analysis Evaluating Molecular Factors of Primary Resistance to Tyrosine Kinase Inhibitors in Metastatic Non Small Cell Lung Cancer Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Aim of the present retrospective study is to evaluate molecular factors of primary resistance to tyrosine kinase inhibitors in metastatic non small cell lung cancer (NSCLC) patients. The investigators assess first, the incidence of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma viral oncogene homolog (KRAS) mutations, SOS and hepatocyte growth factor (HGF) expression, anaplastic lymphoma kinase (ALK) translocation and expression and, secondly, the investigators correlate molecular markers with clinical features and outcome in terms of response rate, progression free survival and overall survival.
Detailed description
Non small cell lung cancer patients.
Conditions
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2010-07-01
- Completion
- 2011-07-01
- First posted
- 2010-07-15
- Last updated
- 2010-07-29
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01163058. Inclusion in this directory is not an endorsement.